Biogen stock forecast.

Biogen Stock Price Forecast Twenty-two analysts who offered stock ratings for Biogen in the last three months forecast the average price in 12 months of $359.06 with a high forecast of $458.00 and ...

Biogen stock forecast. Things To Know About Biogen stock forecast.

Oct 26, 2023 · In the dynamic world of stock trading, analysts and investors closely observe the projected highs and lows of Biogen shares. Our integrated forecast predicts a peak price of $242.58 in the forthcoming 30 days, indicating the zenith of the stock's potential performance. Complete Biogen Inc. stock information by Barron's. View real-time BIIB stock price and news, along with industry-best analysis.Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Nov 30, 2023 · According to the issued ratings of 24 analysts in the last year, the consensus rating for Biogen stock is Moderate Buy based on the current 4 hold ratings and 20 buy ratings for BIIB. The average twelve-month price prediction for Biogen is $326.08 with a high price target of $373.00 and a low price target of $239.00.

Oct 27, 2023 · With the interplay of data, predictions, and real-time performance, Biogen's stock emerges not just as an investment opportunity but as a narrative unfolding in the grand theatre of the financial markets. Each high, low, surge, and dip is a chapter, and every investor, a reader and co-author of this evolving tale. The top 16 shareholders own 51% of the company. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. Every investor in Biogen ...

Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know. Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study. The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group.BIIB Earnings Date and Information. Biogen last released its quarterly earnings results on November 8th, 2023. The biotechnology company reported $4.36 EPS for the quarter, topping analysts' consensus estimates of $3.99 by $0.37. The business had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.40 billion.

Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of Biogen While the precise definition of an insider can be subjective, almost everyone ...(Note: The author of this fundamental analysis is a financial writer and portfolio manager. ) An analysis of the technical chart of Biogen Inc. (BIIB) shows ...Mar 19, 2023 · Biogen stock has dropped about 40% from its record high. ... Eisai forecasts $7.3 billion in worldwide sales for the drug by 2030, according to The Pharma Letter. Today, Biogen's full-year revenue ... TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comBiogen stock ( BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company's new Alzheimer's drug in partnership with Japan’s Eisai ...

2 days ago · BIIB Stock 12 Months Forecast. $316.29. (34.80% Upside) Based on 26 Wall …

The forecasts table above shows the forecast values of the company's stock price for each month. The Rate Forecast column displays the Optimal Average Forecast Price. The MIN Rate column displays a pessimistic forecast for this month. “MAX Rate” is an optimistic forecast. The % Volatility column represents the approximate monthly volatility ...

The Biogen stock prediction results are shown below and presented as a graph, table and text information. Biogen stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Biogen analysts is $ 323.48. Today 200 Day Moving Average is the resistance level (272.92 $).Biogen stock analysts project $9.56 billion in sales, which would fall 6%. They also expect the company to earn an adjusted $15.48 per share, in line with Biogen's reaffirmed outlook for profit to ...Dec 1, 2023 · Biogen last announced its earnings data on November 8th, 2023. The …BIIB Earnings Date and Information. Biogen last released its quarterly earnings results on November 8th, 2023. The biotechnology company reported $4.36 EPS for the quarter, topping analysts' consensus estimates of $3.99 by $0.37. The business had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.40 billion.Biogen Stock Price Forecast Twenty-two analysts who offered stock ratings for Biogen in the last three months forecast the average price in 12 months of $359.06 with a high forecast of $458.00 and ...Karen Andersen Nov 8, 2023. We have slightly lowered our Biogen fair value estimate from $327 to $303 following third-quarter results that were relatively in line with our estimates but reflected ...Biogen Inc. (BIIB) stock forecast and price target. Find the latest Biogen Inc. BIIB analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

The Biogen stock prediction results are shown below and presented as a graph, table and text information. Biogen stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Biogen analysts is $ 323.48. Today 200 Day Moving Average is the resistance level (272.92 $).Jul 20, 2022 · Both metrics beat forecasts, however. Biogen stock analysts were looking for $4.08 in adjusted earnings per share and $2.48 billion in sales, according to FactSet. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comThe latest Biogen stock prices, stock quotes, news, and BIIB history to help you invest and trade smarter. ... The 98 analysts offering price forecasts for Biogen have a median target of 318.83 ...Dec 1, 2023 · The next five years could be even better than the past five, as businesses …Based on analysts offering 12 month price targets for BIIB in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Nov 1, 2023 · The Biogen stock prediction results are shown below and presented as a graph, table and text information. Biogen stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Biogen analysts is $ 323.48. Today 200 Day Moving Average is the resistance level (272.92 $).

Jul 25, 2023 · Revenue from Tysabri, used to treat multiple sclerosis, missed forecasts at $473 million, but Tecfidera beat with $274 million. ... Biogen stock has a 60 Composite Rating out of a best-possible 99. Wednesday, September 27, 2023. No Result . View All ResultHistorical daily share price chart and data for Biogen since 1991 adjusted for splits and dividends. The latest closing stock price for Biogen as of ...Biogen has risen higher in 21 of those 32 years over the subsequent 52-week period, corresponding to a historical accuracy of 65.63%. Is Biogen Stock Undervalued? The current Biogen [ BIIB] share price is $229.57. The Score for BIIB is 31, which is 38% below its historic median score of 50, and infers higher risk than normal.With the interplay of data, predictions, and real-time performance, Biogen's stock emerges not just as an investment opportunity but as a narrative unfolding in the grand theatre of the financial markets. Each high, low, surge, and dip is a chapter, and every investor, a reader and co-author of this evolving tale.According to the issued ratings of 24 analysts in the last year, the consensus rating for Biogen stock is Moderate Buy based on the current 4 hold ratings and 20 buy ratings for BIIB. The average twelve-month price prediction for Biogen is $326.08 with a high price target of $373.00 and a low price target of $239.00.Nov 28, 2023 · The Biogen Inc. stock price fell by -0.603% on the last day (Tuesday, 28th Nov 2023) from $228.79 to $227.41. During the last trading day the stock fluctuated 1.68% from a day low at $223.89 to a day high of $227.65. The price has been going up and down for this period, and there has been a 2.17% gain for the last 2 weeks.

The company said earnings are expected to be between $15.25 and $16.75 per share for this year, more than prior expectation of $14.25 to $16.00.

Wall Street Still Has Questions About Growth. Biogen reported earnings Wednesday that beat Wall Street expectations, but even CEO Christopher Viehbacher acknowledged that investors weren’t ...

About the Biogen, Inc. stock forecast. As of 2023 November 07, Tuesday current price of BIIB stock is 250.350$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).(See Biogen stock forecast on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, ...BIIB Stock 12 Months Forecast. $316.29. (34.80% Upside) Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $316.29 with a high forecast of $373.00 and a low forecast of $242.00. The average price target represents a 34.80% change from the last price of $234.64.Nov 28, 2023 · The Biogen Inc. stock price fell by -0.603% on the last day (Tuesday, 28th Nov 2023) from $228.79 to $227.41. During the last trading day the stock fluctuated 1.68% from a day low at $223.89 to a day high of $227.65. The price has been going up and down for this period, and there has been a 2.17% gain for the last 2 weeks. Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the ...Previous Close $237.21. Volume 681.40K. Average Volume (3M) 872.44K. Market Cap. $34.35B. Enterprise Value $34.86B. Total Cash (Recent Filing) $6.08B. Total Debt (Recent Filing) $6.59B. Price to Earnings (P/E) 12.9.Biogen's (NASDAQ:BIIB) stock is up by 3.0% over the past week. ... To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the ...Nov 21, 2023 · Analyst Future Growth Forecasts. Earnings vs Savings Rate: BIIB's forecast earnings growth (18.1% per year) is above the savings rate (2.2%). Earnings vs Market: BIIB's earnings (18.1% per year) are forecast to grow faster than the US market (14.8% per year). High Growth Earnings: BIIB's earnings are forecast to grow, but not significantly. Biogen's revenues have been falling - from $10.7bn in 2020, to $8.8bn in 2021, and $8bn in 2022, and the company - which remains very profitable, driving net income of $4bn, $1.55bn, and $3bn in ...

The drug could bring in $12.9 billion in sales by 2028, according to GlobalData forecasts. Today, Biogen's annual revenue has declined to about $10 billion from a peak of more than $14 billion, so ...BIIB stock trades at around 13x earnings and the consensus price target suggests the stock could have an 18% upside from its current price. Axsome Therapeutics (AXSM) Source: everything possible ...10.74%. $93.67M. ESALF | Complete Eisai Co. Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Instagram:https://instagram. oil company stocklargest riasnyse metjscp At that time, BIIB stock could surpass analysts’ forecast for 7% stock price growth. And trading at just 14x earnings, Biogen is offering good value for risk-tolerant investors.Dec 1, 2023 · Karen Andersen Nov 8, 2023. We have slightly lowered our Biogen fair … private wealth managmentsales enablement platform market Both metrics beat forecasts, however. Biogen stock analysts were looking for $4.08 in adjusted earnings per share and $2.48 billion in sales, according to FactSet. vagx CLNV Stock Forecast 2023, 2024, 2025, 2030. The Best Financial Tips for Your Financial Success in 2023 https://cavix.orgBiogen Stock Forecast, BIIB stock price prediction. Price target in 14 days: 238.775 USD. …Biogen ( BIIB -0.52%) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. But the way the stock ...